XOMA. Bull or Bear? Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : XOMA. Bull or Bear?

XOMA 32.28

-3.7%

Nov 13 3:54 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: aknahow who wrote (5233)	1/2/1998 8:00:00 PM
From: Robert K.	Read Replies (2) of 17367

George I am begining to wonder what your thinking........................... ....."your theory about really being in a p3 trauma." checked the site and they are still firm on p2" " I was reluctant to repeat the rumor"..... What the heck are you thinking? The trauma trial is THE big one, here is a except from the Nov 5th press release...... Neuprex(tm) Clinical Progress XOMA has completed the design of and is initiating its Phase III pivotal trial to test Neuprex(tm) as a treatment to prevent infections and infectious complications in patients suffering hemorrhage due to trauma. The primary endpoint will be a reduction in the percentage of patients experiencing severe pulmonary complications, i.e., pneumonia and/or acute respiratory distress syndrome (ARDS). The trial is designed to enroll 1,650 patients who receive two or more units of blood as a result of blunt or penetrating trauma. The company has submitted the protocol to more than 40 prospective study sites for approval prior to starting the trial. (gne money "i estimate" at 4-6 mil) due about now

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next